Haploidentical peripheral stem cell transplantation for young patients with severe aplastic anemia using post-transplant cyclophosphamide and methotrexate

Severe aplastic anemia (SAA) is a serious immune-mediated hematopoietic stem cell disorder that presents with a hypocellular marrow and pancytopenia [1,2]. Successful allogeneic hematopoietic stem cell transplantation (HSCT) overcomes the critical comorbidities of SAA and virtually eliminates the risk of relapse and secondary clonal disorders [2]. Recent improvements in HSCT suggest the possibility of matched unrelated donors (MUDs) as alternative first-line treatment in the absence of matched related donors (MRDs) [3-5].

Source: Biology of Blood and Marrow Transplantation - February 18, 2021 Category: Hematology Authors: Kaitai Yang, Susu Gong, Tiebin Jiang, Xinquan Liang, Jian Hu, Ping Zhu, Lin Nie, Yajing Xu, Bin Fu, Bone Marrow Failure Working Group (BMFWG) of Hunan Province Source Type: research